Market closed
LeMaitre Vascular/$LMAT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About LeMaitre Vascular
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
Ticker
$LMAT
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
622
Website
LMAT Metrics
BasicAdvanced
$2.2B
54.66
$1.82
0.89
$0.64
0.64%
Price and volume
Market cap
$2.2B
Beta
0.89
52-week high
$107.03
52-week low
$59.87
Average daily volume
155K
Dividend rate
$0.64
Financial strength
Current ratio
7.74
Quick ratio
5.322
Long term debt to equity
4.713
Total debt to equity
5.535
Dividend payout ratio (TTM)
33.63%
Management effectiveness
Return on assets (TTM)
8.72%
Return on equity (TTM)
13.33%
Valuation
Price to earnings (TTM)
54.665
Price to revenue (TTM)
10.464
Price to book
6.76
Price to tangible book (TTM)
9.82
Price to free cash flow (TTM)
66.56
Dividend yield (TTM)
0.64%
Forward dividend yield
0.64%
Growth
Revenue change (TTM)
14.81%
Earnings per share change (TTM)
49.21%
3-year revenue growth (CAGR)
11.79%
3-year earnings per share growth (CAGR)
11.08%
3-year dividend per share growth (CAGR)
13.41%
What the Analysts think about LMAT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for LeMaitre Vascular stock.
LMAT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
LMAT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
LMAT News
AllArticlesVideos
LeMaitre Will Announce Fourth Quarter 2024 Earnings Results February 27, 2025
GlobeNewsWire·4 weeks ago
The Most Underrated Mistake Destroying Your Retirement - December Dividend Income Report
Seeking Alpha·4 weeks ago
LeMaitre Vascular Announces Proposed Convertible Senior Notes Offering
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for LeMaitre Vascular stock?
LeMaitre Vascular (LMAT) has a market cap of $2.2B as of February 23, 2025.
What is the P/E ratio for LeMaitre Vascular stock?
The price to earnings (P/E) ratio for LeMaitre Vascular (LMAT) stock is 54.66 as of February 23, 2025.
Does LeMaitre Vascular stock pay dividends?
Yes, the LeMaitre Vascular (LMAT) stock pays dividends to shareholders. As of February 23, 2025, the dividend rate is $0.64 and the yield is 0.64%. LeMaitre Vascular has a payout ratio of 33.63% on a trailing twelve-month basis.
When is the next LeMaitre Vascular dividend payment date?
The next LeMaitre Vascular (LMAT) dividend payment date is unconfirmed.
What is the beta indicator for LeMaitre Vascular?
LeMaitre Vascular (LMAT) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.